SecBot SecBot
DEFM14A ·Filed Jun 8, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001104659-26-071107
Notable filing: DEFM14A
Actionable Insight ▲ Bullish

Traders should monitor the shareholder vote on July 8 and regulatory HSR/German clearance. The $3.16 cash price sets an effective floor near that level. CVR upside to $100M aggregate is real but contingent on achieving aggressive 2027 bempedoic acid sales ($300M+) or enbumyst sales ($160M+). If the deal closes, delisting will occur shortly after.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK AT ENTRY AT T+20
Entry
$3.15
T+0 close · Jun 8, 2026 · via day close
Latest settled
0.00%
T+20 · $3.15
Vs SPY
−1.63%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 8 $3.15entry
  2. T+1 · 5mo ago −0.32%α −0.02% · $3.14
  3. T+5 · 5mo ago 0.00%α −2.11% · $3.15
  4. T+20 · 4mo ago 0.00%α −1.63% · $3.15
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plus one CVR per share. The board unanimously recommends a FOR vote. The deal requires majority approval of outstanding shares, with the special meeting on July 8, 2026. Total transaction costs are ~$1.08 billion, funded by $706.1M equity commitments and up to $550M debt. CVRs offer up to $100M in total contingent payments tied to sales milestones.

Key Financial Metrics

Deal Value
$814.0M
Deal Type
acquisition

Key Facts

  • Merger consideration: $3.16/share cash + 1 CVR per share
  • Total funding ~$1.08B: $706.1M equity from ArchiMed funds + up to $550M debt commitment from BPCR/ BioPharma Credit
  • Special meeting July 8, 2026; required vote is majority of outstanding shares (257.7M shares outstanding)
  • CVRs: up to $40M aggregate if U.S. bempedoic acid net sales exceed $300M in CY 2027 (max $350M); up to $60M if enbumyst U.S. net sales exceed $160M in any single CY through 2030
  • Board and financial advisor Centerview Partners opined that consideration is fair from a financial point of view
  • Company termination fee: $34.2M; Parent termination fee: $68.3M
  • Expected close: Q3 2026; HSR and German merger control filings submitted May 15, 2026
  • No dissenting directors; board recommendation was unanimous

Financial Impact

Total transaction size ~$1.08 billion in cash for equity and debt paydown/fees; $3.16/share cash consideration implies ~$814M equity value on 257.7M shares outstanding; up to $100M additional CVR payments contingent on sales milestones

stock pricevaluationdebtdilution

Risk Factors

  • Shareholder vote failure: requires majority of all outstanding shares, not just votes cast, abstentions/failures to vote count as AGAINST
  • Regulatory delay or antitrust conditions from HSR or German Federal Cartel Office
  • CVR payments uncertain and could be zero if sales milestones not met
  • Debt financing terms or conditions may delay close if tranche A funding conditions not satisfied

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
DEFM14A Filing (Primary)0001104659-26-071107
Document: tm2615754-2_defm14a.htm0001104659-26-071107

Track record

21 reports on ESPR

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026